Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.62% is in line with its 5-year average of -19.05%, around the middle of its 5-year range (-51.78%–-2.06%).
45.08% above its 12-month average of -32.09%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.76%.
RETURN ON ASSETS (ROA)
-17.62%
RETURN ON ASSETS (ROA) AVG TTM
-32.09%
RETURN ON ASSETS (ROA) AVG 3Y
-24.12%
RETURN ON ASSETS (ROA) AVG 5Y
-19.05%
RETURN ON ASSETS (ROA) AVG 10Y
-9.28%
RETURN ON ASSETS (ROA) AVG 15Y
-1.20%
RETURN ON ASSETS (ROA) AVG 20Y
0.52%
CURRENT VS TTM AVG
+45.08%
CURRENT VS 3Y AVG
+26.95%
CURRENT VS 5Y AVG
+7.51%
CURRENT VS 10Y AVG
-89.78%
CURRENT VS 15Y AVG
-1366.04%
CURRENT VS 20Y AVG
-3457.71%
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
+42.70%
vs the sector median at left
Myriad Genetics, Inc.
Market Cap
$410.85M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$410.80M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$411.45M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$404.78M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$412.94M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$414.16M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$419.05M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$421.28M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$421.41M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Myriad Genetics, Inc. (MYGN) | $410.85M | -17.62% | -32.09% | -24.12% | -19.05% |
| Neurogene Inc. (NGNE)vs › | $410.80M | -45.47% | -26.84% | -30.13% | -31.02% |
| Shoulder Innovations, Inc. (SI)vs › | $411.45M | -23.05% | -30.00% | -27.77% | -27.77% |
| Carlsmed, Inc. (CARL)vs › | $404.78M | -30.75% | -34.79% | -68.11% | -68.11% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.94M | -71.16% | -43.23% | -31.68% | -18.72% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.16M | -41.33% | -54.52% | -54.52% | -54.52% |
| Prothena Corporation plc (PRTA)vs › | $419.05M | -14.54% | -48.52% | -33.40% | -26.00% |
| Rezolute, Inc. (RZLT)vs › | $421.28M | -68.75% | -55.58% | -51.15% | -46.76% |
| Senseonics Holdings, Inc. (SENS)vs › | $421.41M | -61.86% | -66.50% | -24.17% | -122.74% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $396.99M | -62.39% | -45.13% | -56.85% | -56.85% |
ROA
-17.6%
ROE
-37.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -51.78% |
| 2024-12-31 | -12.39% |
| 2023-12-31 | -22.97% |
| 2022-12-31 | -9.34% |
| 2021-12-31 | -2.06% |
| 2020-12-31 | -15.77% |
| 2020-06-30 | -14.20% |
| 2019-06-30 | 0.29% |
| 2018-06-30 | 11.34% |
| 2017-06-30 | 1.44% |
| 2016-06-30 | 13.31% |
| 2015-06-30 | 10.47% |
| 2014-06-30 | 21.39% |
| 2013-06-30 | 18.31% |
| 2012-06-30 | 16.24% |
| 2011-06-30 | 16.49% |
| 2010-06-30 | 25.65% |
| 2009-06-30 | 18.14% |
| 2008-06-30 | 9.58% |
| 2007-06-30 | -9.31% |
| 2006-06-30 | -13.81% |
| 2005-06-30 | -25.15% |
| 2004-06-30 | -21.57% |
| 2003-06-30 | -13.58% |
| 2002-06-30 | -8.89% |
| 2001-06-30 | -4.17% |
| 2000-06-30 | -8.20% |
| 1999-06-30 | -18.66% |
| 1998-06-30 | -14.54% |
| 1997-06-30 | -12.09% |
